BR112012022797A2 - composição farmacêutica resistente a álcool, e, método para tratar uma doença com uma formulação de agente ativo resistente a álcool - Google Patents
composição farmacêutica resistente a álcool, e, método para tratar uma doença com uma formulação de agente ativo resistente a álcoolInfo
- Publication number
- BR112012022797A2 BR112012022797A2 BR112012022797A BR112012022797A BR112012022797A2 BR 112012022797 A2 BR112012022797 A2 BR 112012022797A2 BR 112012022797 A BR112012022797 A BR 112012022797A BR 112012022797 A BR112012022797 A BR 112012022797A BR 112012022797 A2 BR112012022797 A2 BR 112012022797A2
- Authority
- BR
- Brazil
- Prior art keywords
- alcohol resistant
- disease
- treating
- active agent
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
composição farmacêutica resistente a álcool, e, método para tratar uma doença com uma formulação de agente ativo resistente a álcool. formulações farmacêuticas que resistem à dopagem de dose induzida por etanol e métodos de uso das mesmas.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31208110P | 2010-03-09 | 2010-03-09 | |
US32256710P | 2010-04-09 | 2010-04-09 | |
US32465610P | 2010-04-15 | 2010-04-15 | |
US35395010P | 2010-06-11 | 2010-06-11 | |
US36682510P | 2010-07-22 | 2010-07-22 | |
PCT/US2011/027736 WO2011112709A1 (en) | 2010-03-09 | 2011-03-09 | Alcohol resistant enteric pharmaceutical compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012022797A2 true BR112012022797A2 (pt) | 2018-02-20 |
Family
ID=44560224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012022797A BR112012022797A2 (pt) | 2010-03-09 | 2011-03-09 | composição farmacêutica resistente a álcool, e, método para tratar uma doença com uma formulação de agente ativo resistente a álcool |
Country Status (15)
Country | Link |
---|---|
US (3) | US20110223244A1 (pt) |
EP (1) | EP2544667B1 (pt) |
JP (1) | JP5819329B2 (pt) |
KR (1) | KR101855805B1 (pt) |
CN (1) | CN102869349A (pt) |
AU (1) | AU2011224350B2 (pt) |
BR (1) | BR112012022797A2 (pt) |
CA (1) | CA2792523C (pt) |
EA (1) | EA029077B1 (pt) |
ES (1) | ES2709766T3 (pt) |
HU (1) | HUE042593T2 (pt) |
IL (1) | IL221835A (pt) |
MX (1) | MX339408B (pt) |
SG (2) | SG183993A1 (pt) |
WO (1) | WO2011112709A1 (pt) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
WO2006009602A2 (en) | 2004-06-16 | 2006-01-26 | Tap Pharmaceutical Products, Inc. | Multiple ppi dosage form |
DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
MY153062A (en) * | 2007-10-12 | 2014-12-31 | Takeda Pharmaceuticals Usa Inc | Methods of treating gastrointestinal disorders independent of the intake of food |
TW201105316A (en) | 2009-07-22 | 2011-02-16 | Gruenenthal Gmbh | Hot-melt extruded pharmaceutical dosage form |
KR101747156B1 (ko) | 2009-07-22 | 2017-06-27 | 그뤼넨탈 게엠베하 | 산화-안정화된 탬퍼-내성 용량형 |
PE20131102A1 (es) | 2010-09-02 | 2013-10-12 | Gruenenthal Chemie | Forma de dosificacion resistente a manipulacion que comprende una sal inorganica |
MX348491B (es) | 2011-07-29 | 2017-06-15 | Gruenenthal Gmbh | Tableta a prueba de manipulacion que proporciona liberacion inmediata de fármaco. |
PT2736497T (pt) | 2011-07-29 | 2017-11-30 | Gruenenthal Gmbh | Comprimido resistente a adulteração proporcionando libertação imediata de fármaco |
AU2013248351B2 (en) | 2012-04-18 | 2018-04-26 | Grunenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
US20140141075A1 (en) | 2012-11-21 | 2014-05-22 | Warner Chilcott Company, Llc | 5-aminosalicylic acid capsule formulation |
US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
US10154966B2 (en) | 2013-05-29 | 2018-12-18 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
EA032465B1 (ru) | 2013-07-12 | 2019-05-31 | Грюненталь Гмбх | Защищенная от применения не по назначению пероральная фармацевтическая лекарственная форма, содержащая этиленвинилацетатный полимер, и способ ее изготовления |
JP6480936B2 (ja) | 2013-11-26 | 2019-03-13 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | クライオミリングによる粉末状医薬組成物の調製 |
EP3142646A1 (en) | 2014-05-12 | 2017-03-22 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
CA2910865C (en) | 2014-07-15 | 2016-11-29 | Isa Odidi | Compositions and methods for reducing overdose |
CA2902911C (en) * | 2014-10-31 | 2017-06-27 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
WO2016174664A1 (en) | 2015-04-29 | 2016-11-03 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
EP3346991A1 (en) | 2015-09-10 | 2018-07-18 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
WO2017145146A1 (en) | 2016-02-25 | 2017-08-31 | Dexcel Pharma Technologies Ltd. | Compositions comprising proton pump inhibitors |
US20170296476A1 (en) * | 2016-04-15 | 2017-10-19 | Grünenthal GmbH | Modified release abuse deterrent dosage forms |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
RU2020117757A (ru) * | 2017-11-01 | 2021-11-29 | Эджмонт Фармасьютикалс, Ллк Траст | Оральные фармацевтические композиции лоразепама, устойчивые к спирту |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2806033A (en) * | 1955-08-03 | 1957-09-10 | Lewenstein | Morphine derivative |
JPS60100516A (ja) * | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
US4876094A (en) * | 1984-01-13 | 1989-10-24 | Battelle Development Corporation | Controlled release liquid dosage formulation |
US4599114A (en) * | 1985-02-11 | 1986-07-08 | Atkinson George K | Treatment of titanium dioxide and other pigments to improve dispersibility |
IT1191674B (it) * | 1986-03-07 | 1988-03-23 | Eurand Spa | Formulazioni per la preparazione di farmaci a rilascio prolungato adatte alla somministrazione per via orale |
CH669523A5 (pt) * | 1986-06-25 | 1989-03-31 | Mepha Ag | |
US5202128A (en) * | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
US5023369A (en) * | 1990-06-25 | 1991-06-11 | Monsanto Company | Process for producing N-phosphonomethylglycine |
DE69207863T2 (de) * | 1991-11-13 | 1996-06-05 | Glaxo Canada | Vorrichtung zur kontrollierten Wirkstoffreigabe |
US5266331A (en) * | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
US5968551A (en) * | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
US5273760A (en) | 1991-12-24 | 1993-12-28 | Euroceltigue, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US5662933A (en) * | 1993-09-09 | 1997-09-02 | Edward Mendell Co., Inc. | Controlled release formulation (albuterol) |
GB9401894D0 (en) * | 1994-02-01 | 1994-03-30 | Rhone Poulenc Rorer Ltd | New compositions of matter |
US5399359A (en) * | 1994-03-04 | 1995-03-21 | Edward Mendell Co., Inc. | Controlled release oxybutynin formulations |
US5670163A (en) * | 1994-06-20 | 1997-09-23 | Kv Pharmaceuticals Company | Long acting GI and esophageal protectant |
US5508276A (en) | 1994-07-18 | 1996-04-16 | Eli Lilly And Company | Duloxetine enteric pellets |
US5567754A (en) * | 1995-08-23 | 1996-10-22 | Kerr-Mcgee Corporation | Pigments with improved dispersibility in thermoplastic resins |
EA001773B1 (ru) | 1996-03-08 | 2001-08-27 | Нюкомед Данмарк А/С | Пероральная фармацевтическая форма лекарственного препарата в виде множественной дозированной формы с модифицированным высвобождением |
AUPN969796A0 (en) * | 1996-05-07 | 1996-05-30 | F.H. Faulding & Co. Limited | Taste masked liquid suspensions |
DE19637082A1 (de) * | 1996-09-12 | 1998-03-19 | Boehringer Mannheim Gmbh | Schnellzerfallende Pellets |
SE9604124D0 (sv) * | 1996-11-12 | 1996-11-12 | Pharmacia & Upjohn Ab | Compact member, method of manufacturing and use thereof |
US6312724B1 (en) * | 1997-04-04 | 2001-11-06 | Isa Odidi | Sustained release pharmaceutical matrix tablet of pharmaceutically acceptable salts of diclofenac and process for preparation thereof |
CA2216215A1 (en) * | 1997-04-05 | 1998-10-05 | Isa Odidi | Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity |
ES2263211T3 (es) * | 1997-07-02 | 2006-12-01 | Euro-Celtique S.A. | Formulaciones de tramadol de liberacion sostenida estabilizada. |
IT1298302B1 (it) * | 1998-02-26 | 1999-12-20 | Riccardo Reverso | Produzione di bioproteine per uso zootecnico da siero di latte e scarti di industrie lattiero-casearie |
US6596756B1 (en) * | 1998-09-15 | 2003-07-22 | Eli Lilly And Company | Treatment of fibromyalgia |
US6306425B1 (en) * | 1999-04-09 | 2001-10-23 | Southern Research Institute | Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol |
ATE391495T1 (de) * | 1999-09-30 | 2008-04-15 | Penwest Pharmaceuticals Co | Matrixsystem mit verzögerter freisetzung für hochlösliche wirkstoffe |
AR021347A1 (es) * | 1999-10-20 | 2002-07-17 | Cipla Ltd | Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma |
US20050037073A1 (en) * | 2000-01-13 | 2005-02-17 | Alpharx Inc. | Solid self-emulsifying dosage form for improved delivery of poorly soluble hydrophobic compounds and the process for preparation thereof |
US20020102301A1 (en) * | 2000-01-13 | 2002-08-01 | Joseph Schwarz | Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof |
AR030557A1 (es) * | 2000-04-14 | 2003-08-27 | Jagotec Ag | Una tableta en multicapa de liberacion controlada y metodo de tratamiento |
AP2001002264A0 (en) * | 2000-08-30 | 2001-09-30 | Pfizer Prod Inc | Sustained release formulations for growth hormone secretagogues. |
FR2816840B1 (fr) * | 2000-11-17 | 2004-04-09 | Flamel Tech Sa | Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation |
ES2240313T3 (es) * | 2000-12-07 | 2005-10-16 | Warner-Lambert Company Llc | Procedimiento y sistema para la liberacion uniforme de un farmaco. |
US7199217B2 (en) * | 2000-12-13 | 2007-04-03 | Eli Lilly And Company | Amidated glucagon-like peptide-1 |
US20030049320A1 (en) * | 2000-12-18 | 2003-03-13 | Wockhardt Limited | Novel in-situ forming controlled release microcarrier delivery system |
DE10107663B4 (de) * | 2001-02-19 | 2004-09-09 | Lts Lohmann Therapie-Systeme Ag | Testosteronhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung |
FR2825023B1 (fr) * | 2001-05-23 | 2005-04-15 | Flamel Tech Sa | Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif |
US6960357B2 (en) * | 2001-05-25 | 2005-11-01 | Mistral Pharma Inc. | Chemical delivery device |
US7052706B2 (en) * | 2001-06-08 | 2006-05-30 | Nostrum Pharmaceuticals, Inc. | Control release formulation containing a hydrophobic material as the sustained release agent |
ATE346590T1 (de) * | 2001-07-26 | 2006-12-15 | Ethypharm Sa | Umgehüllte allylamine oder benzylamine enthaltende granulate, verfahren zur herstellung und in der mundhöhle dispergierbare tabletten enthaltend die umgehüllten granulate |
DE20220604U1 (de) * | 2001-07-27 | 2004-02-26 | Yamanouchi Pharmaceutical Co., Ltd. | Zusammensetzung, enthaltend feine Partikel zur Langzeitfreisetzung für schnell in der Mundhöhle zerfallende Tabletten |
US20040170688A1 (en) * | 2001-08-06 | 2004-09-02 | Deshmukh Abhijit Mukund | Enteric formulation of fluoxetin |
US6585997B2 (en) * | 2001-08-16 | 2003-07-01 | Access Pharmaceuticals, Inc. | Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
US20050013862A1 (en) * | 2001-09-05 | 2005-01-20 | Vectura Limited | Functional powders for oral delivery |
EP1429739A1 (en) * | 2001-09-21 | 2004-06-23 | Egalet A/S | Polymer release system |
WO2003024426A1 (en) * | 2001-09-21 | 2003-03-27 | Egalet A/S | Controlled release solid dispersions |
US8101209B2 (en) * | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
GB0125088D0 (en) * | 2001-10-18 | 2001-12-12 | Smithkline Beecham Cork Ltd | New use |
US20030118647A1 (en) * | 2001-12-04 | 2003-06-26 | Pawan Seth | Extended release tablet of metformin |
HRP20020124A2 (en) * | 2002-02-11 | 2003-10-31 | Pliva D D | Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping |
US20030175342A1 (en) * | 2002-03-14 | 2003-09-18 | Karl Kolter | Coated pharmaceutical single-unit delayed-release forms, based on polyvinyl acetate |
FR2837100B1 (fr) * | 2002-03-18 | 2004-07-23 | Flamel Tech Sa | Comprimes a bases de microcapsules a liberation modifiee |
EP1499295A4 (en) * | 2002-04-05 | 2006-04-05 | Penwest Pharmaceuticals Co | EXTENDED RELEASE METOPROLOL FORMULATIONS |
US6958161B2 (en) * | 2002-04-12 | 2005-10-25 | F H Faulding & Co Limited | Modified release coated drug preparation |
FR2842735B1 (fr) * | 2002-07-26 | 2006-01-06 | Flamel Tech Sa | Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os |
US8211462B2 (en) * | 2002-07-30 | 2012-07-03 | Ucb Pharma Gmbh | Hot-melt TTS for administering rotigotine |
DE10234673B4 (de) * | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren |
US8268352B2 (en) * | 2002-08-05 | 2012-09-18 | Torrent Pharmaceuticals Limited | Modified release composition for highly soluble drugs |
US7985422B2 (en) * | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
US8216609B2 (en) * | 2002-08-05 | 2012-07-10 | Torrent Pharmaceuticals Limited | Modified release composition of highly soluble drugs |
US20040185097A1 (en) * | 2003-01-31 | 2004-09-23 | Glenmark Pharmaceuticals Ltd. | Controlled release modifying complex and pharmaceutical compositions thereof |
US20080031901A1 (en) | 2004-09-24 | 2008-02-07 | Abbott Laboratories | Sustained release monoeximic formulations of opioid and nonopioid analgesics |
EP1689367A1 (en) * | 2003-10-21 | 2006-08-16 | Actavis Group HF | Pharmaceutical formulations containing quetiapine |
WO2005046648A1 (en) * | 2003-11-12 | 2005-05-26 | Glenmark Pharmaceuticals Ltd. | Extended release pharmaceutical dosage forms comprising alpha-2 agonist tizanidine |
US20050100594A1 (en) * | 2003-11-12 | 2005-05-12 | Nilendu Sen | Pharmaceutical formulation containing muscle relaxant and COX-II inhibitor |
US20050175695A1 (en) * | 2003-11-25 | 2005-08-11 | Catherine Castan | Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods |
US20050159364A1 (en) * | 2003-12-19 | 2005-07-21 | Cooper Garth J. | Copper antagonist compounds |
US20050163843A1 (en) * | 2003-12-31 | 2005-07-28 | Garth Boehm | Alprazolam formulations |
EP1841414A1 (en) * | 2003-12-31 | 2007-10-10 | Alpharma, Inc. | Rosiglitazone and metformin formulations |
CA2552126A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Ziprasidone formulations |
EP1732513A2 (en) * | 2003-12-31 | 2006-12-20 | Alpharma, Inc. | Rosiglitazone formulations |
US20050232990A1 (en) * | 2003-12-31 | 2005-10-20 | Garth Boehm | Donepezil formulations |
TW200539903A (en) * | 2004-03-12 | 2005-12-16 | Smithkline Beecham Plc | Pharmaceutical formulations |
US20050250838A1 (en) * | 2004-05-04 | 2005-11-10 | Challapalli Prasad V | Formulation for sustained delivery |
BRPI0511663A (pt) * | 2004-06-07 | 2008-01-02 | Wyeth Corp | composição compreendendo água e um componente de sólidos, processo, e, tablete revestido |
US20050276848A1 (en) * | 2004-06-15 | 2005-12-15 | Nilobon Podhipleux | Sustained release neutralized divalproex sodium |
US20050276849A1 (en) * | 2004-06-15 | 2005-12-15 | Nilobon Podhipleux | Sustained release dosage forms |
TWI245966B (en) * | 2004-07-05 | 2005-12-21 | Prodisc Technology Inc | Display device and image processing method therefor |
US20060039975A1 (en) * | 2004-08-20 | 2006-02-23 | Zalman Vilkov | Paroxetine formulations |
US20060051298A1 (en) * | 2004-09-03 | 2006-03-09 | Groenewoud Pieter J | Abuse resistent pharmaceutical dosage and method of making same |
DK2801354T3 (en) * | 2004-10-08 | 2017-05-15 | Forward Pharma As | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
US20060228413A1 (en) * | 2005-02-28 | 2006-10-12 | Penwest Pharmaceuticals Co. | Controlled release venlafaxine formulations |
WO2006119389A2 (en) * | 2005-05-03 | 2006-11-09 | Mutual Pharmaceutical Company, Inc. | Quinine-containing controlled-release formulations |
US20060263429A1 (en) * | 2005-05-20 | 2006-11-23 | Hengsheng Feng | Compressible mixture, compressed pharmaceutical compositions, and method of preparation thereof |
US20060286172A1 (en) * | 2005-06-03 | 2006-12-21 | Anu Mahashabde | Pharmaceutical compositions comprising prostanoid-receptor agonists and methods of making and using the same |
EP2474308A1 (en) * | 2005-06-27 | 2012-07-11 | Valeant International (Barbados) SRL | Pharmaceutical formulations containing bupropion hydrobromide |
AU2006275476A1 (en) * | 2005-08-01 | 2007-02-08 | Alpharma Inc. | Alcohol resistant pharmaceutical formulations |
JP2009510137A (ja) * | 2005-10-07 | 2009-03-12 | アディテック・ファルマ・アクチボラゲット | フマル酸エステルを含む制御放出医薬組成物 |
EP1849460A3 (en) * | 2005-10-31 | 2007-11-14 | ALZA Corporation | Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms |
PL116330U1 (en) | 2005-10-31 | 2007-04-02 | Alza Corp | Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation |
RU2433817C2 (ru) * | 2006-01-21 | 2011-11-20 | Эбботт Гмбх Унд Ко.Кг | Лекарственная форма и способ для доставки вызывающих зависимость лекарственных веществ |
US20070264346A1 (en) | 2006-02-16 | 2007-11-15 | Flamel Technologies | Multimicroparticulate pharmaceutical forms for oral administration |
US20070212414A1 (en) | 2006-03-08 | 2007-09-13 | Penwest Pharmaceuticals Co. | Ethanol-resistant sustained release formulations |
US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
JP2009538315A (ja) * | 2006-05-22 | 2009-11-05 | テバ ファーマシューティカル インダストリーズ リミティド | 塩酸デュロキセチン遅延放出型製剤 |
US20080085304A1 (en) | 2006-10-10 | 2008-04-10 | Penwest Pharmaceuticals Co. | Robust sustained release formulations |
US20080226711A1 (en) | 2007-03-12 | 2008-09-18 | Torrent Pharmaceuticals Ltd. | Pharmaceutical compositions of duloxetine |
US20090017113A1 (en) * | 2007-07-13 | 2009-01-15 | Osinga Niels J | Duloxetine formulations |
EP2219612A4 (en) * | 2007-12-17 | 2013-10-30 | Paladin Labs Inc | CONTROLLED RELEASE FORMULATION AVOIDING IMPROPER USES |
AU2009230676A1 (en) * | 2008-03-24 | 2009-10-01 | Lupin Limited | Delayed release compositions of duloxetine |
KR20120003436A (ko) * | 2009-03-18 | 2012-01-10 | 에보니크 룀 게엠베하 | 중합체 혼합물 및 부형제를 포함하는 코팅을 이용하는, 에탄올의 영향에 대한 내성을 갖는 제어 방출 제약 조성물 |
JP2013504562A (ja) * | 2009-09-17 | 2013-02-07 | カディラ・ヘルスケア・リミテッド | アルコールで誘発される用量ダンピングを低減するための医薬組成物 |
-
2011
- 2011-03-09 BR BR112012022797A patent/BR112012022797A2/pt not_active Application Discontinuation
- 2011-03-09 US US13/044,225 patent/US20110223244A1/en not_active Abandoned
- 2011-03-09 EP EP11754004.7A patent/EP2544667B1/en active Active
- 2011-03-09 MX MX2012010361A patent/MX339408B/es active IP Right Grant
- 2011-03-09 CA CA2792523A patent/CA2792523C/en not_active Expired - Fee Related
- 2011-03-09 ES ES11754004T patent/ES2709766T3/es active Active
- 2011-03-09 SG SG2012067021A patent/SG183993A1/en unknown
- 2011-03-09 SG SG10201504529WA patent/SG10201504529WA/en unknown
- 2011-03-09 CN CN2011800204003A patent/CN102869349A/zh active Pending
- 2011-03-09 JP JP2012557214A patent/JP5819329B2/ja not_active Expired - Fee Related
- 2011-03-09 KR KR1020127025986A patent/KR101855805B1/ko active IP Right Grant
- 2011-03-09 EA EA201290884A patent/EA029077B1/ru not_active IP Right Cessation
- 2011-03-09 HU HUE11754004A patent/HUE042593T2/hu unknown
- 2011-03-09 AU AU2011224350A patent/AU2011224350B2/en not_active Ceased
- 2011-03-09 WO PCT/US2011/027736 patent/WO2011112709A1/en active Application Filing
-
2012
- 2012-09-09 IL IL221835A patent/IL221835A/en not_active IP Right Cessation
-
2014
- 2014-04-29 US US14/264,540 patent/US20140248341A1/en not_active Abandoned
-
2017
- 2017-10-04 US US15/724,767 patent/US20180085315A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
SG183993A1 (en) | 2012-10-30 |
EP2544667B1 (en) | 2018-11-14 |
US20180085315A1 (en) | 2018-03-29 |
MX2012010361A (es) | 2013-02-26 |
AU2011224350B2 (en) | 2015-07-02 |
EA029077B1 (ru) | 2018-02-28 |
JP2013522219A (ja) | 2013-06-13 |
CN102869349A (zh) | 2013-01-09 |
WO2011112709A1 (en) | 2011-09-15 |
EP2544667A4 (en) | 2013-10-02 |
CA2792523A1 (en) | 2011-09-15 |
HUE042593T2 (hu) | 2019-07-29 |
KR20130054943A (ko) | 2013-05-27 |
KR101855805B1 (ko) | 2018-06-25 |
US20140248341A1 (en) | 2014-09-04 |
ES2709766T3 (es) | 2019-04-17 |
IL221835A (en) | 2017-06-29 |
EA201290884A1 (ru) | 2013-03-29 |
AU2011224350A1 (en) | 2012-10-11 |
EP2544667A1 (en) | 2013-01-16 |
SG10201504529WA (en) | 2015-07-30 |
CA2792523C (en) | 2018-01-09 |
MX339408B (es) | 2016-05-24 |
US20110223244A1 (en) | 2011-09-15 |
JP5819329B2 (ja) | 2015-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012022797A2 (pt) | composição farmacêutica resistente a álcool, e, método para tratar uma doença com uma formulação de agente ativo resistente a álcool | |
CR20140365A (es) | Compuestos de carbamato y preparación y uso de los mismos | |
CL2018000299A1 (es) | Composiciones con potenciadores de impregnacion para el suministro de fármacos. | |
CL2015003072A1 (es) | Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas. | |
BR112016028961A8 (pt) | fibras eletrotorcidas, seu método de preparação e seu uso, bem como composição, e kit | |
BRPI0513812B8 (pt) | método para produzir uma composição líquida que compreende 13c-piruvato hiperpolarizado, composição, uso da mesma, radical, e, uso do radical | |
CL2014003225A1 (es) | Composición que comprende un agente de control biológico y un fungicida. | |
BR112014019262A8 (pt) | Composições orais veterinárias parasíticas compreendendo ingredientes ativos de ação sistêmica, métodos e uso das mesmas | |
DOP2010000304A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
AR057946A1 (es) | Formulacion de zonisamida de liberacion sostenidda | |
CL2012002551A1 (es) | Combinacion farmaceutica que comprende por lo menos un 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol de fórmula (i) y por lo menos un antagonista de nmda; composicion farmaceutica; y uso para el tratamiento del dolor. | |
BR112015023922A2 (pt) | composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes | |
CL2012003281A1 (es) | Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica. | |
BR112013008601A8 (pt) | Formulações de emulsão de clevidipina contendo agentes antimicrobianos | |
BRPI0821145B8 (pt) | uso de um anticorpo anti-nr10 como agente preventivo ou terapêutico para prurido | |
CL2013002033A1 (es) | Preparacion oral de desintegracion rapida que comprende granulos que comprenden un medicamento, un agente de desintegracion, un aglutinador, un agente de enmascaramiento y un agente de solubilizacion; metodo de preparacion; su uso para la profilaxis y/o tratamiento de un padecimiento bipolar. | |
CL2015001652A1 (es) | Compuestos derivados de 4-(bifenil-3-il)-7h-imidazo[4,5-c]piridazina, moduladores de la actividad del receptor gabaa; composicion farmaceutica que los comprende; combinacion que los comprende junto a un segundo agente farmaceuticamente activo; metodo de tratamiento del dolor; y su uso para el tratamiento del dolor. | |
CL2007003356A1 (es) | Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades. | |
BR112012013164A2 (pt) | composições farmacêuticas para o estímulo de células-tronco | |
BR112017016087A2 (pt) | formulações para coxim articular adiposo e métodos de uso das mesmas | |
BR112018015367A2 (pt) | carreadores oromucosais de nanofibra para tratamento terapêutico | |
BR112016003584A8 (pt) | composições farmaceuticas e uso das mesmas para regressão de placa acelerada | |
BR112014020271A8 (pt) | Composição farmacêutica e métodos para diminuir a frequência de micção em paciente | |
BR112021017878A2 (pt) | Carbonato de magnésio com superfície reagida, sistema de liberação, formulação de cuidados domiciliares, métodos para preparar um carbonato de magnésio com superfície reagida e para preparar um sistema de liberação, e, uso de um carbonato de magnésio com superfície reagida e de um sistema de liberação | |
BR112012014159A2 (pt) | Combinações terapêuticas de teobromina e um anti-histamínico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
B11T | Dismissal of application maintained [chapter 11.20 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |